10-K: MetaVia Inc. Navigates Cardiometabolic Focus with Positive Clinical Data and Strategic Realignment

MetaVia Inc. announces positive clinical trial results for its MASH and obesity programs, alongside a strategic realignment and corporate name change.

Summary

• MetaVia Inc., a clinical-stage biotechnology company, is focusing on developing novel pharmaceuticals for cardiometabolic diseases, particularly MASH and obesity.
• The company's lead asset, DA-1241, a GPR119 agonist, showed statistically significant reductions in ALT levels in a Phase 2a clinical trial for MASH.
• DA-1241 also demonstrated significant improvements in CAP score and FAST score, indicating a direct hepatic effect.
• DA-1726, a GLP-1 receptor and glucagon receptor dual agonist for obesity, showed positive top-line data in a Phase 1 trial.
• The company is expecting top-line results from the MAD Part 2 study of the DA-1726 Phase 1 trial in April 2025.
• MetaVia has out-licensed NB-01 for painful diabetic neuropathy to MThera Pharma Co., LTD.
• The company's strategy includes advancing DA-1241 and DA-1726 through FDA regulatory processes and exploring additional pipeline and business opportunities.
• As of March 17, 2025, MetaVia had nine full-time employees.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. Positive clinical trial results are tempered by financial concerns and risks associated with drug development and commercialization.

Positives

• DA-1241 was shown to be very well tolerated with mostly mild AEs and no drug related SAEs in the treatment groups with no treatment emergent adverse events (TEAEs) leading to study drug discontinuation.
• DA-1241 has shown strong potential for monotherapy as well as the potential for combination therapy with its strong safety signals.
• DA-1726 has a well understood mechanism and, in preclinical mice models, resulted in improved weight loss compared to semaglutide and tirzepatide.

Negatives

• The company has incurred net losses since inception and anticipates continuing to do so for the foreseeable future.
• There is substantial doubt about the company's ability to continue as a going concern within twelve months from the date the consolidated financial statements were issued.
• The company is dependent on working capital to fund its business plan, and raising additional capital may cause dilution to existing stockholders, restrict operations, or require relinquishing rights to technologies.
• The price of the company's common stock may be volatile and fluctuate substantially, which could result in substantial losses for holders of the common stock.
• The company has identified material weaknesses in its internal control over financial reporting that could, if not remediated, result in material misstatements in its financial statements or impair its ability to produce accurate and timely consolidated financial statements.

Risks

• The company requires additional capital to accomplish its business plan, and failure to obtain necessary capital when needed on acceptable terms, or at all, could force the company to delay, limit, reduce, or terminate its operations.
• Adverse global economic conditions could have a material adverse effect on the company's business, results of operations, financial condition, and liquidity.
• The company may expend its limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.
• Even if the company obtains favorable clinical results, it may not be able to obtain regulatory approval for, or successfully commercialize DA-1241 and DA-1726.
• Delays in the company's clinical trials may lead to a delay in the submission of marketing approval applications and jeopardize its ability to potentially receive approvals and generate revenues from the sale of its products.
• The company faces substantial competition, which may result in others discovering, developing, or commercializing products before or more successfully than it does.
• The company's commercial success depends upon attaining significant market acceptance of its product candidates, if approved, among hospitals, physicians, patients, and healthcare payors.
• If the company is unable to obtain and maintain sufficient intellectual property rights, its competitive position could be harmed.
• The company currently has a small number of employees and consultants, and its future success depends on its ability to retain its executive officers and to attract, retain, and motivate qualified personnel.
• The company may fail to comply with the continued listing requirements of Nasdaq, such that its common stock may be delisted and the price of its common stock and its ability to access the capital markets could be negatively impacted.

Future Outlook

The company plans to advance DA-1241 and DA-1726 through FDA regulatory processes, explore additional pipeline opportunities, and seek additional financing.

Industry Context

The company operates in the competitive pharmaceutical and biotechnology industries, focusing on cardiometabolic diseases, MASH, and obesity, where there is increasing competition and evolving treatment landscapes.

Comparison to Industry Standards

• The document mentions competitors like Madrigal Pharmaceuticals, Novo Nordisk, and Eli Lilly in the MASH and obesity treatment spaces.
• Madrigal Pharmaceuticals has an approved treatment for MASH, while Novo Nordisk's semaglutide (WEGOVY) and Eli Lilly's tirzepatide (Zepbound) are approved for obesity.
• The document highlights the unmet need for obesity treatments that increase energy expenditure, a mechanism DA-1726 aims to address.
• The document mentions survudutide and mazdutide as oxyntomodulin analogues in Phase 3 trials for obesity and MASH, indicating the competitive landscape for DA-1726.

Related Party Transactions

• The company has a license agreement and shared services agreement with Dong-A ST Co., Ltd., a related party, for the development and manufacturing of DA-1241 and DA-1726.
• In June 2024, the company closed on a private placement offering with Dong-A, and received aggregate gross proceeds of $17.0 million, of which $10.0 million was received from Dong-A.

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings.
• Employees may be affected by potential delays or termination of operations due to funding constraints.
• Patients could benefit from successful development and commercialization of new treatments for MASH and obesity.
• The company's ability to meet its obligations to suppliers and creditors depends on its financial stability.

Next Steps

• Finalize the Clinical Study Report (CSR) of the Phase 2a clinical trial in the first half of 2025.
• Explore other combination therapies that can benefit from the mechanism of action of DA-1241 and to expand the target efficacy of DA-1241 for the treatment of MASH.
• Explore various avenues to advance DA-1726 through the FDA approval process, including seeking ways to expedite clinical trials and conducting non-clinical studies.
• Explore adding (i) clinical stage product candidates to diversify and enrich our pipeline and/or (ii) other technologies.

Key Dates

Keywords

MASH, DA-1241, DA-1726, Obesity, Clinical Trials, GPR119 agonist, GLP-1 receptor, Cardiometabolic diseases, Biotechnology, Pharmaceuticals